Key Highlights
● PFSA crashed 50.62% to $13.57 on August 19, 2026, unwinding a spike that had taken shares from about $1 in early July to the high-$20s intraday just a day earlier.
● The plunge followed Profusa's third Reverse Stock Split of the year, a 1-for-4 split effective August 17 that cut shares outstanding to about 605,726.
● The company disclosed a non-binding term sheet to acquire a diagnostics and toxicology Business with roughly $111 million in 2025 revenue, alongside an already-signed option to acquire G3 Vision Labs.
● Profusa's Balance Sheet shows negative stockholders' Equity of about $28.2 million and just $375,000 in cash, meaning every pending Acquisition depends on financing the company doesn't yet have.
Profusa, Inc. (NASDAQ:PFSA) closed August 19, 2026 at $13.57, down 50.62% on the session. That number understates how wild the ride has been. Two days earlier the Berkeley-based biosensor maker's shares closed at $4.53 following its third reverse stock split of the year. By the close on the 19th, the stock had spiked into the high-$20s intraday before collapsing by more than half, a round trip that fits the "500% spike, then crash" framing better than almost any other name on the tape this week.
This isn't a story about a blown Earnings print or a rejected drug. It's a micro-cap biotech with a Market Value near $3.64 million, a share count mechanically shrunk three times in seven months, and a pending acquisition that would hand meaningful control to owners of a $111 million-revenue diagnostics business, the exact recipe for the low-float, high-velocity trading that produced Tuesday's spike and Wednesday's reversal.
Profusa has been restructuring its Capital Structure and business mix at once. A 1-for-4 reverse split took effect August 17, cutting shares outstanding from roughly 2.42 million to about 605,726, the third consolidation since a 1-for-75 split in February and a 1-for-25 split in July. Layered on top: a non-binding term sheet for a diagnostics and toxicology operator, plus an already-signed option to acquire G3 Vision Labs and its lab subsidiaries.
What Happened?
PFSA fell 50.62% to $13.57 on August 19, 2026, with a market cap near $3.64 million. Aggregated market data corroborates the move, showing shares down $13.91 from a prior close near $27.48, with after-hours trading a further 2.73% lower. Volume ran about 1.46 million shares, double the entire post-split share count, underscoring how much of the action was momentum trading. The move followed a frantic August 18 session in which shares spiked roughly 95% premarket to around $8.86 and touched the $12-13 area intraday before sliding on acquisition jitters. Shares are up dramatically from around $1 in early July, the basis for the "500%-plus spike" framing, even as August 19 marks a sharp single-day giveback.
The Catalyst
Three things are verifiable and distinct. First, a mechanical driver: the 1-for-4 reverse split effective August 17, Profusa's third in 2026. Such splits on ultra-thin float stocks routinely produce exaggerated swings, since even modest dollar volume moves the price sharply. Second, a corporate-development catalyst: an 8-K disclosed a non-binding term sheet to acquire a diagnostics and toxicology company with estimated $111 million in 2025 revenue, funded partly via a $7 million subordinated convertible note (9% OID, 7% interest, 18% on default). That structure is one traders read as dilutive, contributing to a roughly 18% slide on August 18 alone. Third, broader speculative dynamics: micro-cap biotech and reverse-split names have drawn heavy Momentum Trading this year, and Profusa's near-empty float made it a natural target. No single dated press release explains the August 19 close-to-close magnitude beyond these compounding dynamics, so the Reversal is best read as the unwind of a speculative, low-float spike rather than a reaction to fresh negative news. That distinction, structural drivers versus an inferred "sell the spike" dynamic, matters for anyone gauging what comes next.
Latest Company Developments
Profusa has remade its Leadership and strategy. Jack Stover was appointed Executive Chairman and CEO effective July 21, 2026, with founder Ben Hwang shifting to President before resigning from the board on July 26. Days later came the option agreement to acquire G3 Vision Labs and subsidiaries Med Screen Laboratories, Dominion Diagnostics, and Acutis Diagnostics, with initial consideration of 201,120 common shares and roughly 52,904 preferred shares; exercise is contingent on $30 million in new financing, Debt refinancing, Nasdaq approval, and a Shareholder vote. A broader non-binding term sheet for a second diagnostics/toxicology target followed. The pivot from a medical-device biosensor company toward a diagnostics roll-up is verified, not speculation.
Financial Position
Profusa's balance sheet explains why dilution fears dominate. It has disclosed negative stockholders' equity of roughly $28.2 million and cash of about $375,000 at the most recent quarter-end, against a trailing net loss north of $36 million and a first-quarter 2026 net loss of $3.46 million. To stay funded, it relies on an equity line with Ascent Partners Fund LLC allowing advances up to 9.99% of shares outstanding (capped at $300,000 per draw) priced at 97% of the ten-day VWAP. It has also fought to retain its Nasdaq Capital Market listing, receiving a Hearings Panel exception in May 2026 contingent on bid-price and equity requirements, the driver behind all three reverse splits this year. With 15 employees and minimal cash, the pending acquisitions would need financing almost entirely through new equity or debt.
Bull Case
Optimists point to G3 Vision Labs' roughly $111 million in estimated 2025 revenue, dwarfing Profusa's own operations, which could turn a pre-revenue biosensor company into a cash-generating diagnostics business if the deal closes. Profusa also retains its Lumee Oxygen Platform, which has secured European CE Mark approval, a legitimate medical-device asset independent of the M&A outcome. Resolving Nasdaq compliance would remove the overhang forcing the repeated splits.
Bear Case
Skeptics note every acquisition remains non-binding or conditional on tens of millions in financing the company doesn't have, given $375,000 in cash and negative equity. The G3 deal alone requires $30 million in new capital just to exercise the option, on top of debt refinancing and shareholder approval. Three reverse splits in seven months signal chronic compliance problems, and the Volatility itself, a roughly 95% spike followed by a 50%-plus crash within 48 hours, is a hallmark of speculative, low-float trading that can reverse further against holders just as easily.
What Investors Should Watch Next
Investors should watch: (1) whether the diagnostics term sheet becomes a binding agreement, and its dilution terms; (2) progress on the G3 Vision Labs option, including the required $30 million financing; (3) Profusa's next Nasdaq compliance update; (4) further Ascent Partners equity-line draws; and (5) the next quarterly filing for cash, burn rate, and going-concern language.
Volatility Before the Verdict
Profusa's August 19 plunge is best understood as the violent unwind of a low-float, reverse-split-fueled spike layered on top of genuine but unfinanced acquisition ambitions. The diagnostics deals could be transformative if they close, but with negative equity, sub-$400,000 cash, and every major transaction contingent on financing the company doesn't yet have, the stock's swings are likely to stay outsized until the capital structure and the M&A get resolved.






Please wait processing your request...